Trial Profile

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab/hyaluronidase (Primary) ; Dexamethasone (Primary) ; Iberdomide (Primary)
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms EXCALIBER-RRMM
Sponsors Celgene Corporation

12 Jun 2025 According to a Bristol Myers Squibb media release, MRD data expected in 2025.
03 Oct 2023 Planned End Date changed from 26 Jan 2033 to 25 Jun 2032.
03 Oct 2023 Planned primary completion date changed from 18 Jun 2027 to 18 Mar 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com